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How PrEPped Are Our Providers?
Assessing Vermont Primary Care Providers’ Knowledge and Awareness
of Pre-Exposure Prophylaxis (PrEP) Options for HIV Prevention

Christopher Flynn

MS3 – Larner College of Medicine at the University of Vermont
Family Medicine Clerkship – Hinesburg Family Practice
AHEC Scholars Core Topic: Current and Emerging Health Issues

Pre-exposure Prophylaxis (PrEP): Medications,
Use Metrics, and Associated Problems
Problem: Constant release of new data/guidelines can be
difficult to keep track of “best” available PrEP medications
and dosing strategies
◦ Approved PrEP medications: Truvada (tenofovir disoproxil fumarateemtricitabine; 2012 FDA approval) & Descovy (tenofovir
alafenamide fumarate-emtricitabine; 2019 FDA approval)
◦ Dosing strategies: once daily pill vs. “on demand”, “event-driven”
(2-1-1)
◦ Further compounded by prior research indicating providers’ lack of
training surrounding PrEP prescribing practices

Estimated PrEP users (as of 2018): 200,000-205,000 (US),
187 (VT)
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HIV Statistics & Associated Costs
Despite rising trend in number of PrEP users, number of cases
per year remains relatively stable
Majority of VT’s cases are in Chittenden county
Estimated lifetime cost for early HIV diagnosis is >$400,000
◦ Prevention is the focus!
◦ $907,375 to VT for HIV federally funded grants/programs (FY2018)

(Vermont)

VT HIV Statistics (as of 2018)
Number of total diagnosed cases

711

Newly diagnosed cases (2018)

18

MSM transmission for newly
diagnosed cases (2018)

43%

Number of PrEP users

187 (94.7% male)

(Vermont)

Perspective of Members of the
Community
One of the main issues we face is not asking the
right screening questions of our patients—for
example, a gay man versus a heterosexual man—
to truly understand their needs. This issue is
further heightened by our patient population.
With a seemingly decreased need for PrEP among
our patients, this is not a situation we routinely
face, thus I would imagine there would be greater
unfamiliarity. Conversely, I would imagine a
greater need for PrEP in regions of the state with a
younger patient demographic.

-Family Medicine Provider

In the last year, as in-person appointments
became restricted, HIV testing access was
consolidated to a few core medical providers,
which resulted in fewer tests and fewer PrEP
referrals. I imagine, also, fewer people continued
their prescriptions for PrEP, along with those more
limited new prescriptions. We anticipate at
Vermont CARES we should be able to resume inperson rapid-result HIV testing this summer, and
consequently we know guided referrals to PrEP
will increase. One dilemma we face now is that
the landscape for referrals and prior routines has
changed dramatically for all providers, so we will
be re-learning protocols for PrEP access in realtime along with those we serve.
-Peter Jacobsen, Executive Director of Vermont CARES

Anne Karakash. (Photographer). (2019). Untitled [Doctor’s Office, Photograph]. Retrieved
05/05/2021, from https://pixabay.com/photos/doctors-office-doctor-office-1944117/

Intervention & Methodology
Reviewed prior Family Medicine Clerkship projects focusing on PrEP as a
novel preventative medicine to compare with multiple options currently
available to patients
Providers (MDs/NPs) at the Hinesburg Family Medicine practice were
asked to complete anonymous survey assessing awareness and
prescribing practices of PrEP

Review of survey data highlighted varying levels of knowledge, as well
as comfortability and confidence discussing PrEP with patients
Goal: Equip providers with updated guidelines to increase knowledge and
confidence when discussing current options for PrEP with patients
Give information sheet to all providers in the practice regarding current clinical guidelines for PrEP

Survey Data Results
All respondents reported
knowledge of PrEP and correctly
identified its purpose

Provider willingness/readiness to
discuss and prescribe PrEP
reported as very willing (60%) or
somewhat willing (40%)

40% reported reading current
PrEP clinical practice guidelines
(CDC)

100% of respondents aware of
Truvada use as PrEP vs. 20%
aware of Descovy use as PrEP

Providers’ familiarity with dosing
regimens:

Top provider-reported barriers
for prescribing PrEP:

• Greater familiarity with once daily dosing
(strongly agree + somewhat agree, 80%)
• Less familiar with “on-demand” dosing
(somewhat agree + neither agree nor
disagree, 100%)

• Cost-related concerns (80%)
• Provider perception of patient risk status
(60%)
• Lack of knowledge, training or experience
with PrEP (40%)
• Time constraint (40%)

Survey Data Results (cont.)

Evaluation of Intervention
“Use it or lose it” phenomenon: relatively low number of PrEP prescriptions in the state potentially
due to low need
◦ Less frequent discussion point between providers and patients, thus providers potentially less likely to keep
current with updated guidelines
◦ Influence of provider’s perspective of perceived need for individual patient or community at large

Survey data along with community member interviews highlight implications of providers’ own biases
impacting patient encounters
Despite small sample size, fair amount of variability emphasizes need for continued education efforts,
especially for minority patient populations

Results of survey are largely qualitative
◦ Potential follow-up 1: Assess differences in PrEP prescribing/counseling practices among providers who
reviewed PrEP info sheet vs. another family medicine practice with similar patient demographics
◦ Potential follow-up 2: Survey providers in the practice who reviewed PrEP info sheet and assess changes in
comfortability and confidence in PrEP counseling/prescribing practices
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